Get started
Author

Kriangkrai Tawinprai

Observed names: K. Tawinprai, Tawinprai, Kriangkrai
ORCID: 0000-0002-2862-948X
Observed ORCID: 0000-0002-2862-948X
OpenAlex ID: A5043632377
Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
2023 · Taweegrit Siripongboonsitti, Teerapat Ungtrakul, et al. · Phytomedicine · 22
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
2022 · Guy Cohen, Pawornrath Jungsomsri, et al. · Human Vaccines & Immunotherapeutics · 17
PDF
Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)
2023 · Taweegrit Siripongboonsitti, Marisa Muadchimkaew, et al. · Scientific Reports · 15
PDF
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
2023 · Taweegrit Siripongboonsitti, Teerapat Ungtrakul, et al. · International Journal of Infectious Diseases · 15
PDF
Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
2022 · Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, et al. · Vaccine · 14
PDF
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
2022 · Saraiorn Thonginnetra, Kriangkrai Tawinprai, et al. · Vaccines · 13
PDF
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
2022 · Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, et al. · Human Vaccines & Immunotherapeutics · 13
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab)
2023 · Taweegrit Siripongboonsitti, Nuttakant Nontawong, et al. · Microbiology Spectrum · 10
Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
2022 · Vimonsri Rangsrisaeneepitak, Thachanun Porntharukchareon, et al. · Diabetology International · 9
PDF
The existence of adrenal insufficiency in patients with COVID-19 pneumonia
2024 · Thachanun Porntharukchareon, Bothamai Dechatech, et al. · Frontiers in Endocrinology · 8
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
2022 · Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, et al. · Vaccines · 8
PDF
The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
2023 · Thachanun Porntharukchareon, Wipada Chartisathian, et al. · Human Vaccines & Immunotherapeutics · 7
Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
2022 · Marisa Muadchimkaew, Taweegrit Siripongboonsitti, et al. · International Journal of Infectious Diseases · 7
PDF
A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)
2024 · Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, et al. · Journal of Infection and Public Health · 6
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine
2022 · Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, et al. · Expert Review of Vaccines · 6
The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
2023 · Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, et al. · Medicina · 5
PDF
Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment
2023 · Walaipan Tantiyavarong, Prakongboon Sungkasubun, et al. · JCO Global Oncology · 5
PDF
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
2022 · Nuttakant Nontawong, Taweegrit Siripongboonsitti, et al. · Annals of Clinical Microbiology and Antimicrobials · 5
PDF
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
2023 · Kriangkrai Tawinprai, Pawornrath Jungsomsri, et al. · Human Vaccines & Immunotherapeutics · 4
PDF
Herpes zoster after COVID-19 vaccination in an adolescent
2022 · Saraiorn Thonginnetra, Piyakan Limtanyakul, et al. · Dermatology Online Journal · 4
PDF
Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
2023 · Bothamai Dechates, Thachanun Porntharukchareon, et al. · Vaccines · 3
PDF
Telehealth for Diabetes Care During Coronavirus Disease 2019 Pandemic
2022 · Thachanun Porntharukchareon, Supanat Worawichawong, et al. · Asia Pacific Journal of Public Health · 3
Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer
2024 · Chayanee Samdaengpan, Prakongboon Sungkasubun, et al. · JCO Global Oncology · 2
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)
2023 · Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, et al. · Journal of Infection and Public Health · 2
Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev)
2024 · Taweegrit Siripongboonsitti, Marisa Muadchimkaew, et al. · Journal of Virus Eradication · 1
Works count: 36
Citation count: 206
H-index: 9
I10-index: 8
Year
Topic
Type